At Castle, we aim to transform disease management by keeping people first — the patients who benefit from the information that our advanced diagnostic tests provide, the clinicians who use our tests to guide disease management decisions, our talented and valued employees, and our investors. For the diseases that our portfolio of tests cover, we believe the traditional approach to developing a treatment plan for cancers and other diseases using clinical and pathology factors alone is inadequate and can be improved by incorporating the personalized information our tests provide. Our innovative portfolio of commercial and pipeline tests targets unmet clinical need along the patient care continuum. We currently market five proprietary tests designed to answer clinical questions and address treatment plan challenges facing physicians in dermatologic cancers, uveal melanoma and Barrett’s esophagus. https://castletestinfo.com
Our test for invasive cutaneous melanoma, DecisionDx®-Melanoma, is a proprietary gene expression profile, or GEP, test that uses an individual patient’s tumor biology to predict the risk of metastasis or recurrence, as well as the risk of sentinel lymph node positivity, independent of traditional staging factors. https://castletestinfo.com/decisiondx-melanoma
DecisionDx®-SCC is our GEP test that predicts the risk of metastasis in patients with cutaneous squamous cell carcinoma, who have one or more risk factors. https://castletestinfo.com/products/decision-dx-scc
DecisionDx®-UM, the standard of care in uveal melanoma staging, is our GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer. https://castletestinfo.com/products/decisiondx-um
Our comprehensive diagnostic offering — myPath® Melanoma and DecisionDx® DiffDx™-Melanoma — provides a highly accurate, objective result to aid dermatopathologists and dermatologists in characterizing suspicious pigmented lesions. https://castletestinfo.com/mypath-melanoma-diffdx-melanoma
TissueCypher® Barrett’s Esophagus is the world’s first precision medicine test designed to predict future development of esophageal cancer in patients with Barrett’s esophagus. https://tissuecypher.com
Together, we believe these commercial products support an estimated total addressable market of approximately $3 billion in the United States. Additionally, in 2021, we announced the launch of our innovative pipeline initiative to develop a genomic test aimed at predicting response to systemic therapy in patients with moderate-to-severe psoriasis, atopic dermatitis and related inflammatory skin conditions. If successful, this pipeline test has the potential to add approximately $1.9 billion to our current estimated U.S. Castle Biosciences (Nasdaq: CSTL) is based in Friendswood, Texas and has laboratory operations in Phoenix, Arizona, and Pittsburgh, Pennsylvania. For more information, please visit www.CastleBiosciences.com.
